Tvardi Therapeutics is trading 12.39% up at $1.21 in pre-market, with no clear catalyst identified.
- The move follows several declining sessions; the October 8 close was $1.08.
- Its latest listed press release, dated September 24, concerns preclinical ulcerative-colitis data; its investor-relations listing shows no October 9 announcement.
- Major U.S. indices are higher pre-market, but that context does not establish the cause of this individual stock move.